Drug prescription in men and women with type-2 diabetes in Stockholm in 1995 and 2001:change over time

Wändell, Per; Gåfvels, Catharina

doi:10.1007/s00228-002-0510-1

Cited by 14 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with diabetes mellitus were less frequently undertreated in this study period compared with the previous study period [5]. Several other studies have reported an increase in lipid‐lowering drug use among diabetic patients [16, 17]. Although smoking cessation effectively reduces CVD risk [18], smokers are more frequently eligible for lipid‐lowering drug use since they have a high absolute risk of CVD.…”

Section: Discussionmentioning

confidence: 99%

Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands

Mantel‐Teeuwisse

Klungel

Boer

et al. 2004

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimTo assess recent trends in undertreatment of hypercholesterolaemia (1998)(1999)(2000)(2001)(2002). MethodsData were obtained from the third cross-sectional examination of the Monitoring Project on Risk Factors for Chronic Diseases ( n = 4878; age 31-70 years), conducted in the Netherlands. Treatment eligibility was established according to Dutch guidelines. Data from the second examination (1993)(1994)(1995)(1996)(1997) were used to assess time trends. The association between demographic variables, cardiovascular disease risk factors, drug use and lipid-lowering medication was assessed using multivariable log istic regression. ResultsOverall, 45.9% [95% confidence interval (CI) 41.4, 50.4] of respondents eligible for treatment were treated, and 17.4% (95% CI 13.9, 20.9) were both treated and controlled (1998)(1999)(2000)(2001)(2002). Treatment increased significantly after 1995, showed a slight decrease in subsequent years until 2000, when treatment increased again. Subgroups less frequently treated for primary prevention included among others males [odds ratio (OR) = 0.08; 95% CI 0.03, 0.21], younger patients (OR = 0.93 per year; 95% CI 0.88, 0.98), diabetics (OR = 0.19; 95% CI 0.07, 0.56), untreated hypertensives (OR = 0.21; 95% CI 0.09, 0.49) and current smokers (OR = 0.09; 95% CI 0.03, 0.25). In secondary prevention, patients with a history of stroke were less likely to receive treatment (OR = 0.41; 95% CI 0.18, 0.94) compared with patients with a history of ischaemic heart disease. ConclusionsTreatment of hypercholesterolaemia has steadily increased over the past 10 years in the Netherlands. However, at present still less than one out of two eligible for treatment is treated, and only about one out of six is both treated and controlled.

show abstract

Section: Discussionmentioning

confidence: 99%

Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands

Mantel‐Teeuwisse

Klungel

Boer

et al. 2004

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…On the contrary, other studies revealed that the probability of an increased risk for CHF with these agents remains high. Even though, their efficacy still need to be demonstrated in outcome trials [33,34,35,36].…”

Section: Discussionmentioning

confidence: 99%

Prescription Pattern Study in Type 2 Diabetes Mellitus in Diabetic out Patients in Private Clinics in Kerman, Iran

Yusefzadeh

Sepehri

Goodarzi

et al. 2014

BJMMR

View full text Add to dashboard Cite

This work was carried out in collaboration between all authors. All authors have substantial contributions to conception and design, acquisition of data or analysis and interpretation of data.Author GY designed the study and wrote the protocol. Author GS managed the analyses of the study and wrote the first draft of the manuscript. Author MS performed the statistical analysis. Author HG collects the data and managed the literature searches.All authors read and approved the final manuscript.

show abstract

“…Several studies have addressed changes in pharmacological treatment in diabetes over time. Some did not focus on specific drug treatments [14, 15], included all diabetes mellitus patients [9] or were based on data from the early 1990s [15–17]. Those that did address treatment changes in the period during and after the publication of the main UKPDS results showed that metformin use increased after 1997 [8–11].…”

Section: Discussionmentioning

confidence: 99%

The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus

Lub

Denig

Berg

et al. 2006

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimsThe aim of this study was to investigate the impact of new insights and revised guidelines on initial and follow-up treatment with antihyperglycaemic drugs over the period 1998-2003. MethodsThe InterAction Database (IADB), which contains pharmacy dispensing data from 53 community pharmacies in the Northern and Eastern part of the Netherlands, was used in this study. Prevalence and incidence rates of oral antihyperglycaemic drug use were calculated for each year. Follow-up treatment was compared for two cohorts of initial users of oral antihyperglycaemic drugs, starting treatment either 1 year before or 1 year after guideline revision. ResultsThe prevalence and incidence rate of oral antihyperglycaemic drug use increased over the study period from 1.8% to 2.4% ( P < 0.001) and 0.3% to 0.4% ( P = 0.04). The proportion of metformin as initial treatment increased rapidly in the observation period from 14% to 50% ( P < 0.001). Initial users of metformin in 2000 received additional treatment with a sulphonylurea in the follow-up period less often compared with those who started metformin in 1998 (46% vs. 60%, P < 0.004). In contrast, initial users of sulphonylurea in 2000 received additional treatment with metformin more often compared with those who started a sulphonylurea in 1998 (42% vs. 36%, P < 0.008). The new drugs, thiazolidinediones and meglitinides, were seldom used as initial treatment ConclusionsNew insights and the revision of the practice guideline were followed by a significant increase in both initial and follow-up treatment with metformin among patients with Type 2 diabetes mellitus.

show abstract

Drug prescription in men and women with type-2 diabetes in Stockholm in 1995 and 2001:change over time

Abstract: Improved metabolic and cardiovascular outcomes were found, but were not correlated with the simultaneous changed prescription pattern, with increased use of combined insulin and oral antidiabetics, of metformin or of lipid-lowering drugs.

Cited by 14 publications

References 25 publications

Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands

Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands

Prescription Pattern Study in Type 2 Diabetes Mellitus in Diabetic out Patients in Private Clinics in Kerman, Iran

The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus

Contact Info

Product

Resources

About